Erratum to “Short ribosomal prophylaxis in the prevention of clinical recurrences of chronic otitis media of children” [Int. J. Pediatr. Otorninolaryngol. 68 (2004) 83–89]

Mora, Renz; Ralli, Giovanni; Passali, Fm; Crippa, Barbara; Ottoboni, Stefano; Mora, Francesco; Barbieri, Marco

doi:10.1016/j.ijporl.2004.06.001

Cited by 6 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ribosomal immunotherapy led to significant improvements in clinical score, immunological parameters, parents' assessment of the patient's symptoms and hearing tests, compared with placebo, in a study of 72 patients aged 6-14 years 75. In addition, a meta-analysis of 19 randomised, double-blind studies, including 1215 children, demonstrated a significantly lower need for surgical procedures with ribosomal immunotherapy (1% vs 7% with placebo) in patients with recurrent AOM 76.…”

mentioning

confidence: 98%

Immunity‐targeted approaches to the management of chronic and recurrent upper respiratory tract disorders in children

Feleszko

Marengo

Vieira

et al. 2019

Clinical Otolaryngology

View full text Add to dashboard Cite

BackgroundUpper respiratory tract infections (URTIs), including rhinitis, nasopharyngitis, tonsillitis and otitis media (OM), comprise of 88% of total respiratory infections, especially in children. Therefore effective prevention and treatment of RTIs remain a high priority worldwide. Preclinical and clinical data highlight the rationale for the use and effectiveness of immunity‐targeted approaches, including targeted immunisations and non‐specific immunomodulation in the prevention and management of recurrent upper RTIs.Objective of reviewThe idea of this review was to summarise the current evidence and address key questions concerning the use of conservative and immunity‐targeted approaches to recurrent and chronic URTIs, with a focus on the paediatric population.Search strategy/Evaluation methodLiterature searches were conducted in March 2017 and updated in September 2017 using: Academic Search Complete; CENTRAL; Health Source: Nursing/Academic Edition; MEDLINE; clinicaltrials.gov; and Cochrane databases. In total, 84 articles were retrieved and reviewed. Two independent researchers focused on primary and secondary endpoints in systematic reviews, meta‐analyses and randomised, controlled trials, using immunity‐directed strategies as the control group or within a subpopulation of larger studies. Existing guidelines and interventional/observational studies on novel applications were also included.ResultsChildren are particularly susceptible to RTIs due to the relative immaturity of their immune systems, as well as other potential predisposing factors such as day care attendance and/or toxic environmental factors (eg increased pathogenic microbial exposure and air pollutants). Recurrent URTIs can affect otherwise healthy children, leading to clinical sequelae and complications, including the development of chronic conditions or the need for surgery. Available pre‐clinical and clinical data highlight the rationale for the use and effectiveness of immunity‐targeted approaches, including targeted immunisations (flu and pneumococcal vaccines) and non‐specific immunomodulation (bacterial lysates), in the prevention and management of recurrent croup, tonsillitis, otitis media, recurrent acute rhinosinusitis and chronic rhinosinusitis.ConclusionsIn this review, we summarise the current evidence and provide data demonstrating that some immunity‐targeted strategies, including vaccination and immunomodulation, have proved effective in the treatment and prevention of recurrent and chronic URTIs in children.

show abstract

mentioning

confidence: 98%

Immunity‐targeted approaches to the management of chronic and recurrent upper respiratory tract disorders in children

Feleszko

Marengo

Vieira

et al. 2019

Clinical Otolaryngology

View full text Add to dashboard Cite

show abstract

“…With the emergence of resistant strains and the change in the distribution of pharyngotonsillitis bacteria over the time, preventive strategies such as ribosomal immunotherapy may represent a valid alternative approach [5,6,9].…”

Section: Discussionmentioning

confidence: 99%

“…On the basis of previous testing, group A underwent ribosomal prophylaxis with Immucytal (1 tablet daily, 8 days a month for 3 months) while group B received a placebo (same dosage for the same period) [1,5,6]. In order to maintain double blind conditions, Immucytal and placebo tablets were identical in shape and size.…”

Section: Methodsmentioning

confidence: 99%

Ribosomal therapy in the prophylaxis of recurrent pharyngotonsillitis in children

Mora¹,

Dellepiane²,

Crippa³

et al. 2007

International Journal of Pediatric Otorhinolaryngology

Self Cite

View full text Add to dashboard Cite

“…Other efficacy parameters, blind, placebo-controlled studies, complied with Good Clinical which varied across different studies, were included as secondary criteria; these included objectively measured outcomes such as the Practice standards, used the product in official registered indicanumber and duration of antibacterial courses, need for other meditions, and administered it at the recommended dosages [49,[52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70] cations such as expectorants, days of hospitalization, and number were considered eligible for the purposes of this review; pharmaof lost school or work days, as well as subjective and less reliable cologic studies were excluded. This yielded 20 studies.…”

Section: Methodsmentioning

confidence: 99%

“…This yielded 20 studies. [49,[52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70] We patient or physician global evaluations of treatment. then selected for review five publications that we considered the As described below, when the results of all 12 trials were most interesting and/or most representative of use of Ribomunyl ® , considered overall, ribosomal immunotherapy was found to have i.e.…”

Section: Methodsmentioning

confidence: 99%

Prevention of Recurrent Respiratory Tract Infections in Children Using a Ribosomal Immunotherapeutic Agent

Bousquet

Fiocchi²

2006

Pediatric Drugs

View full text Add to dashboard Cite

Recurrent respiratory tract infections (RRTIs) in children constitute a serious problem worldwide. Some children experience considerable morbidity as a result of RRTIs and receive repeated courses of antibacterials that are not effective against viral infectious agents and can increase bacterial resistance. Furthermore, the direct and indirect costs of RRTIs to the community are substantial. In this article, we review the available clinical evidence relating to use of the bacterial immunostimulant Ribomunyl for the prevention of RRTIs in children. The product is composed of ribosomal fractions from four bacteria involved in RRTIs as well as a membrane fraction from one of these bacteria (Klebsiella pneumoniae). Ribomunyl stimulates production of specific humoral and secretory antibodies against the four bacterial strains included in the compound. The product also stimulates non-specific immunity. Thus, Ribomunyl stimulates both the innate and acquired immune systems and offers preventive efficacy against both bacterial and viral infections. To perform this review, we searched the MEDLINE database for articles on Ribomunyl and then included only those publications that described placebo-controlled studies, complied with Good Clinical Practice standards, used the product in official registered indications, and administered it at the recommended dosages. In this way, we were able to generate a comprehensive profile of use of the product and draw valid conclusions about its clinical role. In clinical trials of children, Ribomunyl reduced the number of upper or lower RRTIs, the primary outcome measures. Other favorable results relating to efficacy parameters that served as secondary outcome measures in these studies included a reduction in antibacterial treatments, shorter duration of recurrent episodes, reduced need for other medications such as expectorants, smaller number of lost school days or parent absenteeism from work, less fever, and reduced hearing loss. Studies focusing on particular conditions, such as otitis media, or those that included specific patient groups, such as very young children, reported similar findings. Adverse events occurred very rarely and were mild. Their frequency was similar to that reported in placebo groups, and consisted mostly of fever, otorhinolaryngologic symptoms, and cutaneous events. In conclusion, this review clearly demonstrated that Ribomunyl is effective in preventing upper and lower RRTIs in children. Ribomunyl provided a reduction in the number, duration, and severity of infectious episodes and, thereby, reduced antibacterial use and the likelihood of consequent development of bacterial resistance. Ribomunyl also decreased absence from work or school, which has important economic consequences.

show abstract

Erratum to “Short ribosomal prophylaxis in the prevention of clinical recurrences of chronic otitis media of children” [Int. J. Pediatr. Otorninolaryngol. 68 (2004) 83–89]

Cited by 6 publications

References 0 publications

Immunity‐targeted approaches to the management of chronic and recurrent upper respiratory tract disorders in children

Immunity‐targeted approaches to the management of chronic and recurrent upper respiratory tract disorders in children

Ribosomal therapy in the prophylaxis of recurrent pharyngotonsillitis in children

Prevention of Recurrent Respiratory Tract Infections in Children Using a Ribosomal Immunotherapeutic Agent

Contact Info

Product

Resources

About